Pfenex Company Profile (NYSEMKT:PFNX)

About Pfenex (NYSEMKT:PFNX)

Pfenex logoPfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:PFNX
  • CUSIP: N/A
  • Web: N/A
  • Market Cap: $99.45 million
  • Outstanding Shares: 23,455,000
Average Prices:
  • 50 Day Moving Avg: $4.76
  • 200 Day Moving Avg: $7.35
  • 52 Week Range: $4.08 - $11.35
  • Trailing P/E Ratio: 28.24
  • Foreward P/E Ratio: -1.97
  • P/E Growth: -0.05
Sales & Book Value:
  • Annual Revenue: $60.25 million
  • Price / Sales: 1.65
  • Book Value: $3.03 per share
  • Price / Book: 1.40
  • EBIDTA: $5.39 million
  • Average Volume: 107,350 shs.
  • Beta: 4.65
  • Short Ratio: 1.4

Frequently Asked Questions for Pfenex (NYSEMKT:PFNX)

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "PFNX."

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEMKT:PFNX) issued its quarterly earnings results on Monday, May, 8th. The company reported ($0.43) EPS for the quarter, topping the Zacks' consensus estimate of ($0.57) by $0.14. The firm had revenue of $2.80 million for the quarter, compared to analyst estimates of $2.50 million. The business's revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.35) EPS. View Pfenex's Earnings History.

Where is Pfenex's stock going? Where will Pfenex's stock price be in 2017?

2 equities research analysts have issued 12-month price targets for Pfenex's stock. Their forecasts range from $14.00 to $18.00. On average, they anticipate Pfenex's share price to reach $16.00 in the next twelve months. View Analyst Ratings for Pfenex.

Who are some of Pfenex's key competitors?

Who owns Pfenex stock?

Pfenex's stock is owned by many different of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (10.13%), Dow Chemical Co. DE (7.58%), AWM Investment Company Inc. (3.95%), Perceptive Advisors LLC (3.81%), Vanguard Group Inc. (2.64%) and Sanders Morris Harris Inc. (1.77%). Company insiders that own Pfenex stock include Bertrand C Liang, Chemical Co /De/ Dow, Henry W Jr Talbot, Patricia Lady, Patrick K Lucy and Signet Healthcare Partners Acc. View Institutional Ownership Trends for Pfenex.

Who sold Pfenex stock? Who is selling Pfenex stock?

Pfenex's stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Morgan Stanley, UBS Asset Management Americas Inc., JPMorgan Chase & Co., Perceptive Advisors LLC, Nationwide Fund Advisors, DUPONT CAPITAL MANAGEMENT Corp and Bank of New York Mellon Corp. Company insiders that have sold Pfenex stock in the last year include Patricia Lady, Patrick K Lucy and Signet Healthcare Partners Acc. View Insider Buying and Selling for Pfenex.

Who bought Pfenex stock? Who is buying Pfenex stock?

Pfenex's stock was purchased by a variety of institutional investors in the last quarter, including MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Renaissance Technologies LLC, Oxford Asset Management, Bank of America Corp DE, Spark Investment Management LLC, TIAA CREF Investment Management LLC and FMR LLC. View Insider Buying and Selling for Pfenex.

How do I buy Pfenex stock?

Shares of Pfenex can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Pfenex stock cost?

One share of Pfenex stock can currently be purchased for approximately $4.24.

Analyst Ratings

Consensus Ratings for Pfenex (NYSEMKT:PFNX) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.00

Analysts' Ratings History for Pfenex (NYSEMKT:PFNX)
DateFirmActionRatingPrice TargetDetails
8/9/2016MizuhoLower Price TargetBuy$22.00 -> $18.00View Rating Details
5/24/2016Barclays PLCLower Price TargetOverweight$28.00 -> $14.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$25.00 -> $22.00View Rating Details
9/15/2015Evercore ISIInitiated CoverageBuyView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for Pfenex (NYSEMKT:PFNX)
Earnings by Quarter for Pfenex (NYSEMKT:PFNX)
Earnings History by Quarter for Pfenex (NYSEMKT:PFNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.57)($0.43)$2.50 million$2.80 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.66)($0.45)$2.50 million$5.47 millionViewN/AView Earnings Details
11/9/2016Q316($0.56)$1.46$3.18 million$48.82 millionViewListenView Earnings Details
8/8/2016Q216($0.47)($0.43)$2.55 million$3.10 millionViewN/AView Earnings Details
5/9/2016Q116($0.45)($0.35)$2.35 million$2.76 millionViewN/AView Earnings Details
3/10/2016Q415($0.59)($0.37)$2.56 million$3.30 millionViewListenView Earnings Details
11/13/2015Q315($0.46)($0.33)$2.05 million$2.06 millionViewListenView Earnings Details
8/13/2015Q215($0.39)($0.27)$2.07 million$2.30 millionViewListenView Earnings Details
5/14/2015Q115($0.24)($0.29)$2.10 million$2.00 millionViewListenView Earnings Details
3/16/2015Q4($0.20)($0.18)$2.05 million$2.02 millionViewN/AView Earnings Details
11/13/2014Q3($0.25)($0.16)$2.13 million$2.80 millionViewN/AView Earnings Details
8/29/2014($0.15)($1.67)$1.75 million$3.27 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pfenex (NYSEMKT:PFNX)
Current Year EPS Consensus Estimate: $-2.07 EPS
Next Year EPS Consensus Estimate: $-2.15 EPS


Dividend History for Pfenex (NYSEMKT:PFNX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Pfenex (NYSEMKT:PFNX)
Insider Trades by Quarter for Pfenex (NYSEMKT:PFNX)
Institutional Ownership by Quarter for Pfenex (NYSEMKT:PFNX)
Insider Trades by Quarter for Pfenex (NYSEMKT:PFNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017Patricia LadyinsiderSell2,000$4.78$9,560.00View SEC Filing  
1/6/2017Signet Healthcare Partners AccMajor ShareholderSell400$9.50$3,800.00View SEC Filing  
1/5/2017Signet Healthcare Partners AccMajor ShareholderSell7,710$9.50$73,245.00View SEC Filing  
12/29/2016Signet Healthcare Partners AccMajor ShareholderSell24,104$9.66$232,844.64View SEC Filing  
12/27/2016Signet Healthcare Partners AccMajor ShareholderSell104,600$9.58$1,002,068.00View SEC Filing  
12/22/2016Signet Healthcare Partners AccMajor ShareholderSell10,896$9.61$104,710.56View SEC Filing  
11/21/2016Patricia LadyInsiderSell2,000$9.87$19,740.00View SEC Filing  
11/15/2016Patrick K. LucyInsiderSell5,000$10.04$50,200.00View SEC Filing  
8/18/2016Patricia LadyInsiderSell2,000$9.42$18,840.00View SEC Filing  
5/24/2016Patricia LadyCAOSell2,000$6.52$13,040.00View SEC Filing  
5/24/2016Patricia LadyCAOSell2,000$6.52$13,040.00View SEC Filing  
12/15/2015Chemical Co /De/ DowMajor ShareholderSell600,000$11.75$7,050,000.00View SEC Filing  
12/3/2015Patrick K LucyInsiderSell1,500$14.15$21,225.00View SEC Filing  
12/1/2015Bertrand C. LiangCEOSell5,000$14.88$74,400.00View SEC Filing  
12/1/2015Henry W Jr. TalbotVPSell2,000$15.08$30,160.00View SEC Filing  
11/18/2015Patricia LadyCAOSell2,000$14.05$28,100.00View SEC Filing  
11/4/2015Patrick K. LucyinsiderSell1,500$17.54$26,310.00View SEC Filing  
11/2/2015Bertrand C LiangCEOSell5,000$18.01$90,050.00View SEC Filing  
10/2/2015Patrick K LucyInsiderSell1,500$14.98$22,470.00View SEC Filing  
10/1/2015Bertrand C LiangCEOSell5,000$14.78$73,900.00View SEC Filing  
9/3/2015Patricia LadyCAOSell2,000$20.48$40,960.00View SEC Filing  
9/3/2015Patrick K LucyInsiderSell1,500$20.91$31,365.00View SEC Filing  
9/1/2015Bertrand C. LiangCEOSell5,000$21.02$105,100.00View SEC Filing  
7/6/2015Patrick K LucyInsiderSell1,500$19.17$28,755.00View SEC Filing  
7/1/2015Bertrand C LiangCEOSell5,000$19.63$98,150.00View SEC Filing  
6/3/2015Patrick K LucyInsiderSell1,500$20.08$30,120.00View SEC Filing  
6/1/2015Bertrand C LiangCEOSell5,000$18.70$93,500.00View SEC Filing  
5/4/2015Patrick K LucyInsiderSell1,500$13.25$19,875.00View SEC Filing  
5/1/2015Bertrand C LiangCEOSell5,000$13.49$67,450.00View SEC Filing  
4/29/2015Chemical Co /De/ DowMajor ShareholderSell2,232,233$14.57$32,523,634.81View SEC Filing  
4/29/2015James C GaleDirectorSell1,907,767$14.57$27,796,165.19View SEC Filing  
4/2/2015Patrick K LucyInsiderSell1,500$17.62$26,430.00View SEC Filing  
4/1/2015Bertrand C LiangCEOSell5,000$15.27$76,350.00View SEC Filing  
3/4/2015Patrick K LucyInsiderSell1,500$14.36$21,540.00View SEC Filing  
7/29/2014Signet Healthcare Partners AccMajor ShareholderSell380,867$0.31$118,068.77View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Pfenex (NYSEMKT:PFNX)
Latest Headlines for Pfenex (NYSEMKT:PFNX)
DateHeadline logoEdited Transcript of PFNX earnings conference call or presentation 8-May-17 8:30pm GMT - May 9 at 11:09 AM logoPfenex Inc (PFNX) Issues Earnings Results - May 9 at 9:56 AM logoPfenex Reports First Quarter 2017 Results and Provides Business Update - May 8 at 6:36 PM logoPfenex (PFNX) Getting Favorable Press Coverage, Analysis Finds - April 29 at 6:33 PM logoPfenex (PFNX) Receiving Positive Media Coverage, Report Finds - April 25 at 1:53 PM logoPfenex To Report First Quarter 2017 Results and Provide Business Update on Monday, May 8, 2017 - April 24 at 4:38 PM logoETFs with exposure to Pfênex, Inc. : April 13, 2017 - April 13 at 6:59 PM logoWilliam R. Rohn Announces Plans To Retire As Chairman And Board Member - March 31 at 7:20 PM logoPFENEX INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits - March 31 at 7:20 PM logoPfenex Inc (PFNX) Announces Earnings Results - March 16 at 10:43 AM logoPfenex Reports Fourth Quarter and Full Year 2016 Results and Provides Business Update - March 15 at 7:23 PM logoQ4 2016 Pfenex Inc Earnings Release - After Market Close - March 15 at 9:26 AM logoPfenex Inc (PFNX) to Release Quarterly Earnings on Wednesday - March 14 at 8:31 AM logoPfenex To Report Fourth Quarter and Full Year 2016 Results and Provide Business Update on Wednesday, March 15, 2017 - March 1 at 10:02 AM logoPfenex Inc. to Participate in Panel Discussion at 2017 BIO CEO & Investor Conference - February 10 at 8:11 PM logo8:02 am Pfenex announced that Dr. Bertrand C. Liang has resigned his position as CEO, President, Secretary and as a member of the Board of Directors of the Co - January 24 at 7:57 PM logoPfenex Announces Leadership Transition - January 24 at 8:37 AM logoPFENEX INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Other Events, Fi - January 24 at 8:37 AM logoPfenex (PFNX) Catches Eye: Stock Adds 6.6% in Session - November 17 at 10:45 AM logoForm 4 Pfenex Inc. For: Nov 15 Filed by: Lucy Patrick K. - November 16 at 7:05 PM logoPfenex Reports Third Quarter 2016 Results and Provides Business Update - November 10 at 9:55 AM logoEdited Transcript of PFNX earnings conference call or presentation 9-Nov-16 9:30pm GMT - November 10 at 9:55 AM logoQ3 2016 Pfenex Inc Earnings Release - After Market Close - November 9 at 9:24 AM logoPfenex To Report Third Quarter 2016 Results and... - October 26 at 6:49 PM logoMESO Gains After Hours, PFNX Gets It Back, CHRS' Humira Biosimilar Meets Goals - August 9 at 9:59 AM logoPfenex to Regain Full Rights to PF582 and Announces Phase 1/2 Results - August 8 at 7:01 PM logoPfenex reports 2Q loss - August 8 at 7:01 PM logoPfenex Reports Second Quarter 2016 Results and Provides Business Update - August 8 at 7:01 PM logoJazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product … - July 28 at 7:03 PM logo[$$] Road to Launching 'Biosimilar' Drugs Just Got Longer - July 13 at 7:38 AM logo[$$] Gormley's Take: Road to Launching 'Biosimilar' Drugs Just Got Longer - July 13 at 7:30 AM logoPFENEX INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits - July 6 at 5:21 PM logo6 Breakout Stocks Under $10 Set to Soar - May 31 at 7:18 AM


This page was last updated on 5/23/2017 by Staff